Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientif...
September 28 2020 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), an investment company with
innovative medical instrumentation and biotechnology operations
focused on blood volume measurement, today announces the Company
will be exhibiting and showcasing new data at the Heart Failure
Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020
taking place from September 30th - October 6th, 2020.
The Company will host a booth and will be
available online throughout the entire conference to discuss how
Daxor’s BVA-100® blood test improves heart failure outcomes and
answer questions. New data titled “Red Cell Volume Phenotypes in
Hospitalized Heart Failure Patients” (Poster #132) and
“Cost-effectiveness Analysis of Early Blood Volume-Guided
Management in Hospitalized Heart Failure Patients” (Poster #331)
will be highlighted in the Poster Hall accompanied by a narrative
from the principal investigators.
“The HFSA Annual Scientific Meeting is an
exciting venue to increase awareness and utilization of Daxor’s
BVA-100® blood test to improve heart failure outcomes and to share
new data with key thought leaders and decision makers focused on
heart failure research and patient care,” said Michael Feldschuh,
President and CEO of Daxor. “Daxor is the global leader in blood
volume measurement technology and is engaged in numerous research
studies related to the application of BVA technology to improve
heart failure outcomes including a randomized control trial, as
well as next generation test technology development through
contracts awarded by the U.S. Department of Defense.”
Register for the event here:
https://hfsa.org/annualscientificmeeting/registration
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative
medical instrumentation and biotechnology company focused on blood
volume measurement. We developed and market the BVA-100® (Blood
Volume Analyzer), the first diagnostic blood test cleared by the
FDA to provide safe, accurate, objective quantification of blood
volume status and composition compared to patient-specific norms.
The BVA technology has the potential to improve hospital
performance metrics in a broad range of surgical and medical
conditions, including heart failure and critical care, by informing
treatment strategies, resulting in significantly improved patient
outcomes. Our mission is to partner with clinicians to incorporate
BVA technology into standard clinical practice and improve the
quality of life for patients. For more information, please visit
our website at Daxor.com
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Bret ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024